celecoxib has been researched along with Lung Neoplasms in 171 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 9.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 9.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "Alpha-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-alpha-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice." | 7.72 | Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. ( Kline, K; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Sun, L; Zhang, S, 2004) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Although pulmonary dosing of large porous particles has been shown to sustain drug delivery for a few days, there are no reports on safety or long term delivery." | 5.39 | Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. ( Dhanda, DS; Kompella, UB; Mirvish, SS; Tyagi, P, 2013) |
| " Chronic administration of butylated hydroxytoluene (BHT) to mice stimulates pulmonary inflammation characterized by vascular leakage and macrophage infiltration into the air spaces, increased PGE2 production, and translocation of 5-lipoxygenase (5-LO) from the cytosol to the particulate fraction." | 5.31 | Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. ( Barrett, BS; Bauer, AK; Dwyer-Nield, LD; Kisley, LR; Malkinson, AM; Thompson, DC, 2002) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 5.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 5.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| " The main toxicities were grades 1 and 2 nausea and esophagitis, and they were independent of the dose of celecoxib or radiotherapy schedule." | 5.11 | A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. ( Blumenschien, G; Brown, B; Chang, JY; Cox, JD; Fossella, F; Guerrero, T; Jeter, M; Kies, M; Komaki, R; Liao, Z; Milas, L; Smith, CM; Yuan, C, 2005) |
| " One novel lncRNA relevant to inflammation and arachidonic acid (AA) metabolism is the p50-associated COX-2 extragenic RNA (PACER)." | 4.12 | PACER lncRNA regulates COX-2 expression in lung cancer cells. ( Desind, SZ; Iacona, JR; Lutz, CS; Mitrofanova, A; Yu, CY, 2022) |
| "To validate the efficacy of an innovative multimodality therapy with transcatheter arterial embolization (TAE) plus octreotide and celecoxib in reducing neoangiogenesis and prolonging the survival of rabbits with hepatocellular carcinoma." | 3.79 | Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. ( Fu, P; Gao, JH; Huang, ZY; Li, X; Tang, CW; Tong, H; Wen, FQ; Wen, SL; Zhang, CL, 2013) |
| "Celecoxib prevents lung metastasis in a murine model of Ewing sarcoma with no effect on tumor size or neovascularization." | 3.77 | Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. ( Edelman, M; Gendy, AS; Glick, RD; Lipskar, A; Soffer, SZ; Steinberg, BM, 2011) |
| "Celecoxib significantly reduced establishment of metastases by circulating tumor cells in a murine model." | 3.73 | Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer. ( Backhus, LM; Bart, RD; Bremner, RM; Castanos, R; Lin, GY; Sievers, E; Starnes, VA, 2006) |
| "Alpha-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-alpha-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice." | 3.72 | Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. ( Kline, K; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Sun, L; Zhang, S, 2004) |
| "The primary endpoint was postoperative pain and adverse events, and the secondary endpoint was the length of the analgesic procedure and physiological function on postoperative day 1." | 2.94 | Intercostal block vs. epidural analgesia in thoracoscopic lung cancer surgery: a randomized trial. ( Hamano, K; Hayashi, M; Murakami, J; Tanaka, T; Ueda, K; Utada, K, 2020) |
| "Celecoxib with CCRT was well tolerated; the incidence of symptomatic radiation pneumonitis was 6." | 2.90 | Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. ( Bi, N; Chen, D; Deng, L; Feng, Q; Fu, Z; Hu, C; Hui, Z; Liang, J; Liu, L; Lv, J; Wang, J; Wang, L; Wang, W; Wang, X; Xiao, Z; Yang, X; Zhang, T; Zhou, Z, 2019) |
| "It has been suggested that the optimal treatment for cachexia should be a multimodal intervention." | 2.84 | A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. ( Balstad, TR; Bye, A; Fallon, M; Fayers, P; Fearon, K; Johns, N; Kaasa, S; Laird, BJA; Pettersen, CH; Solheim, TS; Stene, GB, 2017) |
| " The endpoints were overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), objective response rate (ORR), disease control rate (DCR), pathological complete response (pCR), and adverse events (AEs)." | 2.82 | The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Chen, XW; Gao, P; Huang, XZ; Li, JY; Li, TH; Li, Y; Song, YX; Sun, JX; Wu, ZH; Ye, SY; Zhao, JH, 2022) |
| "Patients with clinical stage II or III rectal cancer were treated with radiotherapy of 44 Gy in 22 fractions." | 2.79 | Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. ( Chen, HC; Chen, HH; Chen, WT; Chien, CR; Hsiao, CF; Lee, HH; Lin, TC; Lin, TY; Liu, TW; Wang, LW, 2014) |
| "Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity." | 2.78 | Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. ( Bergman, B; Clinchy, B; Ek, L; Fohlin, H; Lamberg, K; Lindgren, A; Lindskog, M; Sederholm, C; Sörenson, S, 2013) |
| "Celecoxib was continued for 2 years or until progression." | 2.76 | Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. ( Bae, K; Choy, H; Extermann, M; Gore, E; Langer, C; Movsas, B; Okunieff, P; Videtic, G, 2011) |
| "Cancer cachexia is a syndrome of progressive weight loss." | 2.76 | A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. ( Bird, SP; Keogh, JW; MacLeod, RD; Rogers, ES; Stewart, J, 2011) |
| "Non-small cell lung cancer is the primary cause of cancer-related death in Western countries." | 2.75 | Biological activity of celecoxib in the bronchial epithelium of current and former smokers. ( Eapen, GA; Hong, WK; Jimenez, CA; Kim, ES; Kurie, JM; Lee, JJ; Liu, DD; Lotan, R; Mao, L; Morice, RC; Newman, RA; Tang, X; Wistuba, II, 2010) |
| "In a single-institution phase II study, we sought to determine the effectiveness of concurrent chemoradiation given with celecoxib and examined biomarkers to predict response to COX-2 inhibition." | 2.74 | A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. ( Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F, 2009) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Treatment with Celecoxib significantly reduced Ki-67 LI in smokers by 35% (P = 0." | 2.72 | Celecoxib decreases Ki-67 proliferative index in active smokers. ( Adams, B; Burdick, M; Dubinett, SM; Fishbein, MC; Goodglick, L; Holmes, C; Hong, L; Mao, JT; Roth, MD; Strieter, ER; Tashkin, DP, 2006) |
| " The alteration of irinotecan pharmacokinetic parameters observed may not be clinically relevant." | 2.72 | Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. ( Argiris, A; Avram, MJ; Kut, V; Luong, L, 2006) |
| "This study defines the OBD of celecoxib when combined with a fixed dose of EGFR TKI." | 2.72 | A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. ( Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C, 2006) |
| "Celecoxib was administered at 400 mg/day during the entire course of radiotherapy." | 2.71 | Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. ( Bonomi, MR; Cabalar, ME; Castro, MA; Cerchietti, LC; Navigante, AH; Roth, BM, 2005) |
| "Lung cancer is the most typical form of cancer that results in death worldwide." | 1.91 | Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression. ( Asif, M; Kashan Theba, F; Khalid, Z; Mujtaba Ali, M; Qadir, A; Rizvi, F, 2023) |
| "Lung cancer is a principal cause of death worldwide, and its treatment is very challenging." | 1.72 | Simultaneous pulmonary administration of celecoxib and naringin using a nebulization-friendly nanoemulsion: A device-targeted delivery for treatment of lung cancer. ( Alhnan, MA; Nasr, M; Said-Elbahr, R; Sammour, O; Taha, I, 2022) |
| "The significant tumor reducing potential of pioglitazone combined with celecoxib was observed (p < 0." | 1.72 | Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer. ( Kiran, AVVVR; Krishnamurthy, PT; Kumari, GK, 2022) |
| "Celecoxib is an inhibitor of cyclooxygenase-2, a gene that is often aberrantly expressed in the lung squamous cell carcinoma (LSQCC)." | 1.48 | Identification of key genes and long non‑coding RNAs in celecoxib‑treated lung squamous cell carcinoma cell line by RNA‑sequencing. ( Gan, C; Li, G; Luo, Q; Wang, X, 2018) |
| "Lung cancer is one of the highest health risks caused by ionizing radiation, which induces both direct effects and non-targeted effects." | 1.48 | Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib. ( Hei, TK; Hu, W; Li, B; Li, P; Nie, J; Pei, H; Sun, F; Zhou, G, 2018) |
| "Lung cancer is one of most common types of cancer worldwide." | 1.48 | Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes. ( Hong, SW; Hur, DY; Jin, DH; Kim, B; Kim, D; Kim, J; Kim, S; Kim, YS, 2018) |
| "An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes has recently emerged from clinical and animal studies." | 1.46 | Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea. ( Almendros, I; Campillo, N; Farré, R; Gozal, D; Montserrat, JM; Navajas, D; Nonaka, PN; Picado, C; Roca-Ferrer, J; Torres, M; Vilaseca, A, 2017) |
| "Inflammation is a potent promoter of tumor metastasis." | 1.42 | Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. ( Bi, Y; Han, M; Jiang, M; Li, S; Xu, J; Xu, X, 2015) |
| " As long-term use of COX-2 inhibitors (COX-2i) can promote thrombo-embolic events, we tested an alternative target, prostaglandin E2 receptor EP4 subtype (EP4), downstream of COX-2." | 1.40 | Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. ( Girish, GV; Lala, PK; Liu, L; Majumder, M; Xin, X, 2014) |
| "We recently demonstrated that both murine and human carcinomas grow significantly slower in mice on low carbohydrate (CHO), high protein diets than on isocaloric Western diets and that a further reduction in tumor growth rates occur when the low CHO diets are combined with the cyclooxygenase-2 inhibitor, celecoxib." | 1.40 | A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. ( Adomat, HH; Bennewith, KL; Dang, NH; Guns, ES; Hamilton, MJ; Ho, VW; Hsu, BE; Krystal, G; Samudio, I; Weljie, A, 2014) |
| "We found that both PGE2 level and A549 metastasis were enhanced in mice with unilateral pulmonary resection following tail vein injection of lung cancer A549 cells." | 1.40 | Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway. ( Da, L; Feng, D; Jiang, F; Li, M; Xu, L; Yang, X; Yin, R; Zhang, S; Zhang, Z, 2014) |
| "Murine prostate cancer cells (RM9) were intravenously injected and lung metastasis was estimated by counting colonies in the lungs." | 1.40 | Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells. ( Akira, S; Amano, H; Ikeda, M; Iwamura, M; Kitasato, H; Majima, M; Satoh, T; Tabata, K; Takahashi, R, 2014) |
| "Treatment with celecoxib had effects on inflammation response and reduced cancer metastasis." | 1.39 | Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. ( Bi, Y; Han, M; Jia, J; Jiang, M; Liu, Q; Xu, J; Xu, X, 2013) |
| "Celecoxib treatment activated Cdc25C and inhibited p21 expression in both unirradiated and irradiated cells, regardless of COX-2 expression." | 1.39 | Different cell cycle modulation by celecoxib at different concentrations. ( Kim, YM; Pyo, H, 2013) |
| "Evaluation of in-vivo anticancer activity of aerosolized Celecoxib encapsulated Nanolipidcarriers (Cxb-NLC) as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against non-small cell lung cancer." | 1.39 | Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. ( Chougule, MB; I, T; Patel, AR; Patlolla, R; Singh, M; Wang, G, 2013) |
| " This study aims to explore the effect of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer A549 cells." | 1.39 | [Effects of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer]. ( Bai, H; Wang, C; Xia, H; Ye, J, 2013) |
| "Although pulmonary dosing of large porous particles has been shown to sustain drug delivery for a few days, there are no reports on safety or long term delivery." | 1.39 | Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. ( Dhanda, DS; Kompella, UB; Mirvish, SS; Tyagi, P, 2013) |
| "Cisplatin is used to treat lung cancer; however, it is also a known carcinogen." | 1.38 | Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice. ( Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Mimoto, J; Okada, T; Sato, K; Takigawa, N; Tanimoto, M; Ueoka, H, 2012) |
| "The sites of secondary metastasis and the associated inflammatory microenvironment were evaluated." | 1.37 | Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. ( Ghosh, S; Gruber, HE; Mukherjee, P; Pathangey, LB; Roy, LD; Tinder, TL, 2011) |
| "Perifosine is an orally bioavailable alkylphospholipid currently being tested in phase II clinical trials as a potential anticancer drug." | 1.35 | Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. ( Elrod, HA; Khuri, FR; Sun, SY; Yue, P, 2009) |
| "Lung and bone metastasis and the associated inflammatory milieu were evaluated in the arthritic versus the non-arthritic mice." | 1.35 | Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. ( Das Roy, L; Gruber, HE; Mukherjee, P; Pathangey, LB; Schettini, JL; Tinder, TL, 2009) |
| "Celecoxib (Celebrex) is a cyclooxygenase-2 (COX-2) selective inhibitor and gefitinib (Iressa(R), ZD1839) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for human non-small cell lung cancer (NSCLC)." | 1.35 | The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. ( Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH, 2009) |
| "There is a substantial degree of variability between NSCLC cell lines in response to SPI, both alone and in combination with cisplatin." | 1.35 | Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. ( El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009) |
| " We carried out the in vitro study using selective COX-2 inhibitor celecoxib combined with EGFR-tyrosine kinase inhibitor (EGFR-TKI) ZD1839 on NSCLC cell lines to investigate the anti proliferation effect and the cell molecular mechanism." | 1.35 | Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. ( Chen, L; He, Y; Huang, H; Liao, H; Wei, W, 2008) |
| "Celecoxib by itself was found to have no effects on cell growth or apoptosis in any of the cell lines." | 1.34 | Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. ( Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A, 2007) |
| "Lung cancer is the leading cause of cancer deaths in the United States." | 1.34 | Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. ( Crooks, PA; Nakshatri, H; Neelakantan, S; Ralstin, M; Schmidt, CM; Sweeney, CJ; Vegeler, RC; Wu, H; Yip-Schneider, MT, 2007) |
| "Chemotherapy for the treatment of brain metastases arising from non-small cell lung cancer (NSCLC) has been limited by poor efficacy and high toxicity." | 1.33 | [A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]. ( Hada, M; Horiuchi, T, 2005) |
| "Celecoxib is a potent inhibitor of tumor growth of secondary bone tumors in vivo which can be explained by its anti-angiogenic and pro-apoptotic effects." | 1.33 | The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. ( Abdollahi, A; Ewerbeck, V; Gebhard, MM; Huber, PE; Klenke, FM; Sckell, A, 2006) |
| "Lung cancer is one of the most common causes of cancer death worldwide." | 1.33 | Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. ( Chen, CS; Kehrer, JP; Tong, Z; Wu, X, 2006) |
| "Cotreatment with celecoxib abrogated the increase in levels of PGE(2) but not COX-2 induced by chemotherapy." | 1.33 | Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. ( Altorki, NK; Dannenberg, AJ; Duffield-Lillico, AJ; Golijanin, D; Port, JL; Subbaramaiah, K; Thaler, HT; Zhang, F, 2005) |
| "Celecoxib-treated A549 tumors had marginal reduction of total and perfused blood vessels compared with untreated controls." | 1.32 | Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. ( Chen, Y; Ding, I; Fenton, B; Finkelstein, J; Guo, M; Hu, D; Keng, P; Liang, L; Liu, W; Okunieff, P; Wang, W, 2003) |
| "Celecoxib treatment decreased cell survival, activated caspase cascades, and increased DNA fragmentation, all of which were abrogated when caspase 8 expression was silenced with caspase 8 siRNA." | 1.32 | Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. ( Khuri, FR; Liu, X; Sun, SY; Yue, P; Zhou, Z, 2004) |
| "Lung cancer is by far the leading cause of cancer-related deaths." | 1.32 | Celecoxib: a novel treatment for lung cancer. ( Abou-Issa, H; Alshafie, G, 2004) |
| "Celecoxib was effective even when administered 12 h after CSC treatment." | 1.32 | Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2 ( Aggarwal, BB; Shishodia, S, 2004) |
| "Treatment with celecoxib significantly reduced calcium ionophore-stimulated PGE2 production from AMs recovered from smokers." | 1.32 | Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. ( Baratelli, F; Dubinett, SM; Holmes, EC; Mao, JT; Roth, MD; Serio, KJ; Strieter, RM; Zhu, L, 2003) |
| "Amiloride is an effective plasminogen activator inhibitor, while celecoxib is a cylcooxygenase-2 inhibitor." | 1.32 | Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. ( Evans, DM; Sloan Stakleff, KD, 2004) |
| " Chronic administration of butylated hydroxytoluene (BHT) to mice stimulates pulmonary inflammation characterized by vascular leakage and macrophage infiltration into the air spaces, increased PGE2 production, and translocation of 5-lipoxygenase (5-LO) from the cytosol to the particulate fraction." | 1.31 | Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. ( Barrett, BS; Bauer, AK; Dwyer-Nield, LD; Kisley, LR; Malkinson, AM; Thompson, DC, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 88 (51.46) | 29.6817 |
| 2010's | 71 (41.52) | 24.3611 |
| 2020's | 12 (7.02) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, H | 1 |
| Huang, X | 1 |
| Xu, S | 1 |
| Shen, H | 1 |
| Zhang, P | 4 |
| Huang, Y | 1 |
| Jiang, J | 2 |
| Sun, Y | 1 |
| Jiang, B | 1 |
| Wu, X | 2 |
| Yao, H | 1 |
| Xu, J | 3 |
| Desind, SZ | 1 |
| Iacona, JR | 1 |
| Yu, CY | 1 |
| Mitrofanova, A | 1 |
| Lutz, CS | 1 |
| Rahal, BA | 1 |
| Bardaweel, SK | 1 |
| Said-Elbahr, R | 1 |
| Nasr, M | 1 |
| Alhnan, MA | 1 |
| Taha, I | 1 |
| Sammour, O | 1 |
| Ye, SY | 1 |
| Li, JY | 1 |
| Li, TH | 1 |
| Song, YX | 1 |
| Sun, JX | 1 |
| Chen, XW | 1 |
| Zhao, JH | 1 |
| Li, Y | 2 |
| Wu, ZH | 1 |
| Gao, P | 1 |
| Huang, XZ | 1 |
| Kothayer, H | 1 |
| Rezq, S | 1 |
| Abdelkhalek, AS | 1 |
| Romero, DG | 1 |
| Elbaramawi, SS | 1 |
| Qadir, A | 1 |
| Khalid, Z | 1 |
| Kashan Theba, F | 1 |
| Mujtaba Ali, M | 1 |
| Asif, M | 1 |
| Rizvi, F | 1 |
| Ueda, K | 1 |
| Hayashi, M | 1 |
| Murakami, J | 1 |
| Tanaka, T | 1 |
| Utada, K | 1 |
| Hamano, K | 1 |
| He, D | 1 |
| Song, E | 2 |
| Jiang, M | 5 |
| Song, Y | 2 |
| Bi, N | 1 |
| Liang, J | 1 |
| Zhou, Z | 2 |
| Chen, D | 1 |
| Fu, Z | 1 |
| Yang, X | 2 |
| Feng, Q | 1 |
| Hui, Z | 1 |
| Xiao, Z | 1 |
| Lv, J | 1 |
| Wang, X | 8 |
| Zhang, T | 1 |
| Deng, L | 1 |
| Wang, W | 2 |
| Wang, J | 1 |
| Liu, L | 4 |
| Hu, C | 1 |
| Wang, L | 2 |
| Lee, R | 1 |
| Choi, YJ | 1 |
| Jeong, MS | 1 |
| Park, YI | 1 |
| Motoyama, K | 1 |
| Kim, MW | 1 |
| Kwon, SH | 1 |
| Choi, JH | 1 |
| Kobayashi, K | 1 |
| Kaira, K | 1 |
| Kagamu, H | 1 |
| Kiran, AVVVR | 1 |
| Kumari, GK | 1 |
| Krishnamurthy, PT | 1 |
| Ziaei, E | 1 |
| Emami, J | 1 |
| Rezazadeh, M | 1 |
| Kazemi, M | 1 |
| Edelman, MJ | 4 |
| Hodgson, L | 3 |
| Cheney, RT | 1 |
| Baggstrom, MQ | 1 |
| Thomas, SP | 1 |
| Gajra, A | 3 |
| Bertino, E | 1 |
| Reckamp, KL | 5 |
| Molina, J | 1 |
| Schiller, JH | 1 |
| Mitchell-Richards, K | 1 |
| Friedman, PN | 1 |
| Ritter, J | 1 |
| Milne, G | 1 |
| Hahn, OM | 1 |
| Stinchcombe, TE | 1 |
| Vokes, EE | 3 |
| Solheim, TS | 1 |
| Laird, BJA | 1 |
| Balstad, TR | 1 |
| Stene, GB | 1 |
| Bye, A | 1 |
| Johns, N | 1 |
| Pettersen, CH | 1 |
| Fallon, M | 1 |
| Fayers, P | 1 |
| Fearon, K | 1 |
| Kaasa, S | 1 |
| Zhang, B | 2 |
| Jin, K | 1 |
| Jiang, T | 1 |
| Shen, S | 1 |
| Luo, Z | 1 |
| Tuo, Y | 1 |
| Liu, X | 4 |
| Hu, Y | 1 |
| Pang, Z | 1 |
| Gulyas, M | 1 |
| Mattsson, JSM | 1 |
| Lindgren, A | 2 |
| Ek, L | 3 |
| Lamberg Lundström, K | 1 |
| Behndig, A | 1 |
| Holmberg, E | 2 |
| Micke, P | 1 |
| Bergman, B | 3 |
| Kim, J | 1 |
| Hong, SW | 1 |
| Kim, S | 1 |
| Kim, D | 1 |
| Hur, DY | 1 |
| Jin, DH | 1 |
| Kim, B | 1 |
| Kim, YS | 2 |
| Li, G | 3 |
| Luo, Q | 1 |
| Gan, C | 1 |
| Wu, C | 2 |
| Li, X | 2 |
| Zhang, D | 1 |
| Xu, B | 1 |
| Hu, W | 2 |
| Zheng, X | 1 |
| Zhu, D | 1 |
| Zhou, Q | 1 |
| Yi, L | 1 |
| Zhang, W | 1 |
| Zhang, H | 3 |
| Shen, J | 1 |
| Zou, J | 1 |
| Luo, P | 1 |
| Zhang, J | 1 |
| Pei, H | 1 |
| Sun, F | 1 |
| Li, P | 1 |
| Nie, J | 1 |
| Li, B | 1 |
| Hei, TK | 1 |
| Zhou, G | 1 |
| Jin, YH | 1 |
| Li, WH | 1 |
| Bai, Y | 1 |
| Ni, L | 1 |
| Dhanda, DS | 1 |
| Tyagi, P | 1 |
| Mirvish, SS | 1 |
| Kompella, UB | 1 |
| Johnson, K | 1 |
| Notrica, DM | 1 |
| Carpentieri, D | 1 |
| Jaroszewski, D | 1 |
| Henry, MM | 1 |
| Ramer, R | 1 |
| Walther, U | 1 |
| Borchert, P | 1 |
| Laufer, S | 1 |
| Linnebacher, M | 2 |
| Hinz, B | 2 |
| Takahashi, R | 1 |
| Amano, H | 2 |
| Satoh, T | 1 |
| Tabata, K | 1 |
| Ikeda, M | 1 |
| Kitasato, H | 2 |
| Akira, S | 1 |
| Iwamura, M | 1 |
| Majima, M | 2 |
| Mandegary, A | 1 |
| Torshabi, M | 1 |
| Seyedabadi, M | 1 |
| Amirheidari, B | 1 |
| Sharif, E | 1 |
| Ghahremani, MH | 1 |
| Xia, H | 1 |
| Ye, J | 1 |
| Bai, H | 1 |
| Wang, C | 1 |
| Zhang, S | 2 |
| Da, L | 1 |
| Feng, D | 1 |
| Yin, R | 1 |
| Li, M | 2 |
| Zhang, Z | 2 |
| Jiang, F | 1 |
| Xu, L | 1 |
| Wang, LW | 1 |
| Hsiao, CF | 1 |
| Chen, WT | 1 |
| Lee, HH | 1 |
| Lin, TC | 1 |
| Chen, HC | 1 |
| Chen, HH | 1 |
| Chien, CR | 1 |
| Lin, TY | 1 |
| Liu, TW | 1 |
| Krysan, K | 4 |
| Kusko, R | 1 |
| Grogan, T | 1 |
| O'Hearn, J | 1 |
| Walser, TC | 1 |
| Garon, EB | 1 |
| Lenburg, ME | 1 |
| Sharma, S | 3 |
| Spira, AE | 1 |
| Elashoff, D | 3 |
| Dubinett, SM | 9 |
| Mu, XY | 1 |
| Dong, XL | 1 |
| Sun, J | 2 |
| Ni, YH | 1 |
| Dong, Z | 1 |
| Li, XL | 1 |
| Sun, EL | 1 |
| Yi, Z | 1 |
| Li, Z | 3 |
| Wang, K | 2 |
| An, MW | 1 |
| Mandrekar, SJ | 1 |
| Sargent, DJ | 1 |
| Majumder, M | 1 |
| Xin, X | 1 |
| Girish, GV | 1 |
| Lala, PK | 1 |
| Chen, J | 1 |
| Shen, P | 1 |
| Zhang, XC | 1 |
| Zhao, MD | 1 |
| Zhang, XG | 1 |
| Yang, L | 1 |
| Ho, VW | 1 |
| Hamilton, MJ | 1 |
| Dang, NH | 1 |
| Hsu, BE | 1 |
| Adomat, HH | 1 |
| Guns, ES | 1 |
| Weljie, A | 1 |
| Samudio, I | 1 |
| Bennewith, KL | 1 |
| Krystal, G | 1 |
| Rosas, C | 1 |
| Sinning, M | 1 |
| Ferreira, A | 1 |
| Fuenzalida, M | 1 |
| Lemus, D | 1 |
| Ogawa, F | 1 |
| Eshima, K | 1 |
| Ito, Y | 1 |
| Matsui, Y | 1 |
| Hosono, K | 1 |
| Iyoda, A | 1 |
| Iwabuchi, K | 1 |
| Kumagai, Y | 1 |
| Satoh, Y | 1 |
| Narumiya, S | 1 |
| Ren, F | 1 |
| Fan, M | 1 |
| Mei, J | 1 |
| Wu, Y | 1 |
| Liu, C | 1 |
| Pu, Q | 1 |
| You, Z | 1 |
| Liu, S | 1 |
| Zhao, Q | 1 |
| Li, S | 2 |
| Peng, Y | 1 |
| Han, M | 3 |
| Ren, P | 1 |
| Xu, X | 2 |
| Bi, Y | 2 |
| Balansky, R | 1 |
| Ganchev, G | 1 |
| Iltcheva, M | 1 |
| Nikolov, M | 1 |
| La Maestra, S | 1 |
| Micale, RT | 1 |
| D'Agostini, F | 1 |
| Steele, VE | 1 |
| De Flora, S | 1 |
| Koczywas, M | 1 |
| Cristea, MC | 1 |
| Dowell, JE | 1 |
| Wang, HJ | 1 |
| Gardner, BK | 2 |
| Milne, GL | 2 |
| Figlin, RA | 3 |
| Fishbein, MC | 3 |
| Elashoff, RM | 2 |
| Hou, LC | 1 |
| Huang, F | 1 |
| Xu, HB | 1 |
| Li, N | 1 |
| Li, H | 1 |
| Su, F | 1 |
| Li, J | 1 |
| Ma, X | 2 |
| Gong, P | 1 |
| Schellhorn, M | 1 |
| Haustein, M | 1 |
| Frank, M | 1 |
| Liu, R | 1 |
| Xu, KP | 1 |
| Tan, GS | 1 |
| Cha, BK | 1 |
| Hwang, KE | 1 |
| Cho, KH | 2 |
| Oh, SH | 1 |
| Kim, BR | 1 |
| Jun, HY | 1 |
| Yoon, KH | 1 |
| Jeong, ET | 1 |
| Kim, HR | 1 |
| Zang, Y | 1 |
| Lee, JJ | 2 |
| Liu, NB | 1 |
| Zhuang, HQ | 1 |
| Zhao, LJ | 1 |
| Yuan, ZY | 1 |
| Wang, P | 1 |
| Campillo, N | 1 |
| Torres, M | 1 |
| Vilaseca, A | 1 |
| Nonaka, PN | 1 |
| Gozal, D | 1 |
| Roca-Ferrer, J | 1 |
| Picado, C | 1 |
| Montserrat, JM | 1 |
| Farré, R | 1 |
| Navajas, D | 1 |
| Almendros, I | 1 |
| Kassam, A | 1 |
| Mandel, K | 1 |
| Gadgeel, SM | 4 |
| Wozniak, A | 3 |
| Ruckdeschel, JC | 2 |
| Heilbrun, LK | 2 |
| Venkatramanamoorthy, R | 2 |
| Chaplen, RA | 1 |
| Kraut, MJ | 2 |
| Kalemkerian, GP | 2 |
| Park, W | 1 |
| Oh, YT | 1 |
| Han, JH | 1 |
| Pyo, H | 5 |
| Falandry, C | 1 |
| Debled, M | 1 |
| Bachelot, T | 1 |
| Delozier, T | 1 |
| Crétin, J | 1 |
| Romestaing, P | 1 |
| Mille, D | 1 |
| You, B | 1 |
| Mauriac, L | 1 |
| Pujade-Lauraine, E | 1 |
| Freyer, G | 1 |
| Schneider, BJ | 1 |
| Wozniak, AJ | 1 |
| Worden, FP | 1 |
| Smith, DW | 1 |
| Chen, W | 1 |
| Kilic, A | 1 |
| Schuchert, MJ | 1 |
| Luketich, JD | 1 |
| Landreneau, RJ | 1 |
| El-Hefnawy, T | 1 |
| Ko, JC | 1 |
| Wang, LH | 1 |
| Jhan, JY | 1 |
| Ciou, SC | 1 |
| Hong, JH | 1 |
| Lin, ST | 1 |
| Lin, YW | 1 |
| Arúajo, AM | 1 |
| Mendez, JC | 1 |
| Coelho, AL | 1 |
| Sousa, B | 1 |
| Barata, F | 1 |
| Figueiredo, A | 1 |
| Amaro, T | 1 |
| Azevedo, I | 1 |
| Soares, M | 1 |
| Mutter, R | 1 |
| Lu, B | 1 |
| Carbone, DP | 2 |
| Csiki, I | 3 |
| Moretti, L | 1 |
| Johnson, DH | 5 |
| Morrow, JD | 3 |
| Sandler, AB | 2 |
| Shyr, Y | 2 |
| Ye, F | 1 |
| Choy, H | 3 |
| Lee, SY | 1 |
| Choi, HK | 1 |
| Lee, KJ | 1 |
| Jung, JY | 1 |
| Hur, GY | 1 |
| Jung, KH | 1 |
| Kim, JH | 1 |
| Shin, C | 1 |
| Shim, JJ | 1 |
| In, KH | 1 |
| Kang, KH | 1 |
| Yoo, SH | 1 |
| Grushka, JR | 1 |
| Ryckman, J | 1 |
| Mueller, C | 1 |
| Roessingh, Ade B | 1 |
| Walton, JM | 1 |
| St Vil, D | 1 |
| Laberge, JM | 1 |
| Bernard, C | 1 |
| Nguyen, VH | 1 |
| Puligandla, PS | 1 |
| Kye, SH | 1 |
| Tashkin, DP | 3 |
| Roth, MD | 4 |
| Adams, B | 2 |
| Nie, WX | 1 |
| Mao, JT | 5 |
| Das Roy, L | 1 |
| Pathangey, LB | 2 |
| Tinder, TL | 2 |
| Schettini, JL | 1 |
| Gruber, HE | 2 |
| Mukherjee, P | 2 |
| Liu, H | 2 |
| Yang, Y | 2 |
| Xiao, J | 2 |
| Lv, Y | 2 |
| Liu, Y | 2 |
| Yang, H | 2 |
| Zhao, L | 2 |
| Elrod, HA | 1 |
| Yue, P | 5 |
| Khuri, FR | 5 |
| Sun, SY | 5 |
| Kim, ES | 1 |
| Hong, WK | 3 |
| Mao, L | 1 |
| Morice, RC | 1 |
| Liu, DD | 1 |
| Jimenez, CA | 1 |
| Eapen, GA | 1 |
| Lotan, R | 4 |
| Tang, X | 1 |
| Newman, RA | 5 |
| Wistuba, II | 1 |
| Kurie, JM | 1 |
| Szabo, E | 2 |
| Klenke, FM | 2 |
| Abdollahi, A | 2 |
| Bischof, M | 1 |
| Gebhard, MM | 2 |
| Ewerbeck, V | 2 |
| Huber, PE | 2 |
| Sckell, A | 2 |
| Gendy, AS | 1 |
| Lipskar, A | 1 |
| Glick, RD | 1 |
| Steinberg, BM | 1 |
| Edelman, M | 1 |
| Soffer, SZ | 1 |
| Gore, E | 2 |
| Bae, K | 1 |
| Langer, C | 1 |
| Extermann, M | 1 |
| Movsas, B | 1 |
| Okunieff, P | 2 |
| Videtic, G | 1 |
| Koch, A | 1 |
| Sederholm, C | 2 |
| Kosieradzki, J | 1 |
| Lamberg, K | 2 |
| Thaning, L | 1 |
| Ydreborg, SO | 1 |
| Sörenson, S | 2 |
| Aberle, DR | 1 |
| Zhang, ZF | 1 |
| Rao, JY | 1 |
| Goodglick, L | 2 |
| Holmes, EC | 2 |
| Cameron, RB | 1 |
| Elashoff, R | 1 |
| Kim, YM | 2 |
| Roy, LD | 1 |
| Ghosh, S | 1 |
| Christenson, R | 1 |
| Jewell, S | 2 |
| Vokes, E | 1 |
| Kratzke, R | 1 |
| Groen, HJ | 1 |
| Sietsma, H | 1 |
| Vincent, A | 1 |
| Hochstenbag, MM | 1 |
| van Putten, JW | 1 |
| van den Berg, A | 1 |
| Dalesio, O | 1 |
| Biesma, B | 1 |
| Smit, HJ | 1 |
| Termeer, A | 1 |
| Hiltermann, TJ | 1 |
| van den Borne, BE | 1 |
| Schramel, FM | 1 |
| Rogers, ES | 1 |
| MacLeod, RD | 1 |
| Stewart, J | 1 |
| Bird, SP | 1 |
| Keogh, JW | 1 |
| Wang, A | 1 |
| Merchan, JR | 1 |
| Halmos, B | 1 |
| Printz, C | 1 |
| Ma, J | 1 |
| George, SL | 1 |
| Okada, T | 1 |
| Takigawa, N | 1 |
| Kishino, D | 1 |
| Katayama, H | 1 |
| Kuyama, S | 1 |
| Sato, K | 1 |
| Mimoto, J | 1 |
| Ueoka, H | 1 |
| Tanimoto, M | 1 |
| Kiura, K | 1 |
| Ninomiya, I | 1 |
| Nagai, N | 1 |
| Oyama, K | 1 |
| Hayashi, H | 1 |
| Tajima, H | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Liu, Q | 1 |
| Jia, J | 1 |
| Fohlin, H | 1 |
| Lindskog, M | 1 |
| Clinchy, B | 1 |
| Tong, H | 1 |
| Zhang, CL | 1 |
| Gao, JH | 1 |
| Wen, SL | 1 |
| Huang, ZY | 1 |
| Wen, FQ | 1 |
| Fu, P | 1 |
| Tang, CW | 1 |
| Wang, ZL | 1 |
| Fan, ZQ | 1 |
| Jiang, HD | 1 |
| Qu, JM | 1 |
| Patel, AR | 1 |
| Chougule, MB | 1 |
| I, T | 1 |
| Patlolla, R | 1 |
| Wang, G | 1 |
| Singh, M | 5 |
| Gao, X | 1 |
| Wang, F | 1 |
| Shen, G | 1 |
| Sang, Y | 1 |
| Zhao, J | 1 |
| Wei, Y | 1 |
| Kisley, LR | 1 |
| Barrett, BS | 1 |
| Dwyer-Nield, LD | 1 |
| Bauer, AK | 1 |
| Thompson, DC | 1 |
| Malkinson, AM | 1 |
| Altorki, NK | 3 |
| Keresztes, RS | 2 |
| Port, JL | 2 |
| Libby, DM | 1 |
| Korst, RJ | 1 |
| Flieder, DB | 1 |
| Ferrara, CA | 1 |
| Yankelevitz, DF | 1 |
| Subbaramaiah, K | 2 |
| Pasmantier, MW | 1 |
| Dannenberg, AJ | 2 |
| Natale, RB | 1 |
| Liao, Z | 3 |
| Milas, L | 3 |
| Komaki, R | 3 |
| Stevens, C | 1 |
| Cox, JD | 2 |
| Liu, W | 1 |
| Chen, Y | 1 |
| Keng, P | 1 |
| Finkelstein, J | 1 |
| Hu, D | 1 |
| Liang, L | 1 |
| Guo, M | 1 |
| Fenton, B | 1 |
| Ding, I | 1 |
| Diperna, CA | 1 |
| Bart, RD | 4 |
| Sievers, EM | 2 |
| Ma, Y | 1 |
| Starnes, VA | 4 |
| Bremner, RM | 4 |
| Serio, KJ | 1 |
| Baratelli, F | 1 |
| Zhu, L | 1 |
| Strieter, RM | 1 |
| Cerchietti, LC | 3 |
| Navigante, AH | 3 |
| Peluffo, GD | 1 |
| Diament, MJ | 1 |
| Stillitani, I | 1 |
| Klein, SA | 1 |
| Cabalar, ME | 2 |
| Yang, P | 3 |
| Chan, D | 1 |
| Felix, E | 2 |
| Cartwright, C | 1 |
| Menter, DG | 1 |
| Madden, T | 2 |
| Klein, RD | 1 |
| Fischer, SM | 1 |
| Hada, M | 2 |
| Shishodia, S | 2 |
| Aggarwal, BB | 2 |
| Koul, D | 1 |
| Põld, M | 1 |
| Põld, A | 1 |
| Dohadwala, M | 2 |
| Heuze-Vourc'h, N | 1 |
| Riedl, KL | 1 |
| Lawson, KA | 1 |
| Simmons-Menchaca, M | 1 |
| Sun, L | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
| Abou-Issa, H | 1 |
| Alshafie, G | 1 |
| Evans, DM | 1 |
| Sloan Stakleff, KD | 1 |
| Bonomi, MR | 1 |
| Castro, MA | 2 |
| Roth, BM | 1 |
| Nugent, FW | 1 |
| Mertens, WC | 1 |
| Graziano, S | 1 |
| Levitan, N | 1 |
| Collea, R | 1 |
| Marshall, J | 1 |
| McCann, J | 1 |
| Haynes, A | 1 |
| Shaik, MS | 4 |
| Chatterjee, A | 4 |
| Schroeder, CP | 3 |
| Lotan, D | 2 |
| Yuan, C | 1 |
| Kies, M | 1 |
| Chang, JY | 1 |
| Jeter, M | 1 |
| Guerrero, T | 1 |
| Blumenschien, G | 1 |
| Smith, CM | 1 |
| Fossella, F | 1 |
| Brown, B | 1 |
| Spano, JP | 1 |
| Chouahnia, K | 1 |
| Morère, JF | 1 |
| Zhang, F | 1 |
| Golijanin, D | 1 |
| Thaler, HT | 1 |
| Duffield-Lillico, AJ | 1 |
| Backhus, LM | 3 |
| Lin, Y | 2 |
| Starnes, M | 1 |
| Castanos, R | 2 |
| Blackhall, F | 1 |
| Papakotoulas, PI | 1 |
| Danson, S | 1 |
| Thatcher, N | 1 |
| Jackson, T | 2 |
| Argiris, A | 2 |
| Kut, V | 1 |
| Luong, L | 1 |
| Avram, MJ | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Boruban, C | 1 |
| Silay, YS | 1 |
| Sandler, A | 2 |
| Oates, J | 1 |
| Williams, MK | 1 |
| Dang, T | 1 |
| Kang, HK | 1 |
| Lee, E | 1 |
| Lim, SJ | 1 |
| Cherukuri, DP | 1 |
| Nelson, MA | 1 |
| Horiuchi, T | 1 |
| Petasis, NA | 1 |
| Uddin, J | 1 |
| Schönthal, AH | 3 |
| Hong, L | 1 |
| Burdick, M | 1 |
| Strieter, ER | 1 |
| Holmes, C | 1 |
| Mernitz, H | 1 |
| Smith, DE | 1 |
| Zhu, AX | 1 |
| Wang, XD | 1 |
| Suganuma, M | 1 |
| Kurusu, M | 1 |
| Suzuki, K | 1 |
| Tasaki, E | 1 |
| Fujiki, H | 1 |
| Tong, Z | 1 |
| Chen, CS | 1 |
| Kehrer, JP | 1 |
| Fulzele, SV | 2 |
| Tucker, C | 1 |
| Sievers, E | 1 |
| Lin, GY | 1 |
| Park, JS | 1 |
| Jun, HJ | 1 |
| Cho, MJ | 1 |
| Lee, JS | 1 |
| Zo, JI | 1 |
| Kadara, H | 1 |
| Woo, JK | 1 |
| Lee, HY | 1 |
| André, T | 1 |
| Tournigand, C | 1 |
| Mineur, L | 1 |
| Fellague-Chebra, R | 1 |
| Flesch, M | 1 |
| Mabro, M | 1 |
| Hebbar, M | 1 |
| Postel Vinay, S | 1 |
| Bidard, FC | 1 |
| Louvet, C | 1 |
| de Gramont, A | 1 |
| Lilenbaum, R | 1 |
| Socinski, MA | 1 |
| Hart, LL | 1 |
| Hariharan, S | 1 |
| Morrison, ME | 1 |
| Fayyad, R | 1 |
| Bonomi, P | 2 |
| Gradilone, A | 2 |
| Silvestri, I | 1 |
| Scarpa, S | 1 |
| Morrone, S | 1 |
| Gandini, O | 1 |
| Pulcinelli, FM | 2 |
| Gianni, W | 1 |
| Frati, L | 2 |
| Aglianò, AM | 2 |
| Gazzaniga, P | 2 |
| Heath, EI | 1 |
| De Ruysscher, D | 1 |
| Bussink, J | 1 |
| Rodrigus, P | 1 |
| Kessels, A | 1 |
| Dirx, M | 1 |
| Houben, R | 1 |
| Wanders, R | 1 |
| Harris, RE | 1 |
| Beebe-Donk, J | 1 |
| Alshafie, GA | 1 |
| Chen, S | 1 |
| Lotti, LV | 1 |
| Martino, S | 1 |
| Mattiello, T | 1 |
| Ali, S | 1 |
| Philip, PA | 1 |
| Ahmed, F | 1 |
| Sarkar, FH | 1 |
| Vegeler, RC | 1 |
| Yip-Schneider, MT | 1 |
| Ralstin, M | 1 |
| Wu, H | 1 |
| Crooks, PA | 1 |
| Neelakantan, S | 1 |
| Nakshatri, H | 1 |
| Sweeney, CJ | 1 |
| Schmidt, CM | 1 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Mottolese, M | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Sperduti, I | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Ferretti, G | 1 |
| Tomao, S | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Chen, L | 1 |
| He, Y | 1 |
| Huang, H | 1 |
| Liao, H | 1 |
| Wei, W | 1 |
| Backlund, MG | 1 |
| Amann, JM | 1 |
| Watson, D | 1 |
| Morrison, C | 1 |
| Kratzke, RA | 1 |
| Mauer, AM | 1 |
| Masters, GA | 1 |
| Bedor, M | 1 |
| Green, MJ | 1 |
| Mao, J | 1 |
| Inge, L | 1 |
| Rajasekaran, A | 1 |
| Agarwala, A | 1 |
| Fisher, W | 1 |
| Bruetman, D | 1 |
| McClean, J | 1 |
| Taber, D | 1 |
| Titzer, M | 1 |
| Juliar, B | 1 |
| Yu, M | 1 |
| Breen, T | 1 |
| Einhorn, LH | 1 |
| Hanna, N | 1 |
| Fidler, MJ | 1 |
| Patel, JD | 1 |
| Villaflor, VM | 1 |
| Coon, J | 1 |
| Buckingham, L | 1 |
| Kaiser, K | 1 |
| Basu, S | 1 |
| Kempen, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer[NCT01503385] | Phase 2 | 100 participants (Anticipated) | Interventional | 2011-12-31 | Recruiting | ||
| A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer[NCT01041781] | Phase 3 | 313 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to DSMB recommendation) | ||
| A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study[NCT01419145] | 46 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Evaluation Of Celecoxib In Combination With Weekly Docetaxel In Elderly (70 Years) Or Poor Performance Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)[NCT00030407] | Phase 2 | 34 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy[NCT00030420] | Phase 2 | 24 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| A Phase I/II Trial of a COX-2 Inhibitor, Celebrex (Celecoxib), [National Screening Committee# 719627] With Limited Field Radiation for Intermediate Prognosis Patients With Locally Advanced Non-Small Cell Lung Cancer, With Analysis of Prognostic Factors[NCT00046839] | Phase 1/Phase 2 | 21 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Cox-2-Inhibitor and Chemotherapy in Non-Small Cell Lung Cancer. A Prospective Randomized Double-Blind Study[NCT00300729] | Phase 3 | 319 participants (Actual) | Interventional | 2006-05-31 | Active, not recruiting | ||
| 0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients[NCT00771953] | Phase 2 | 109 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Oral L-arginine Supplementation in Patients With Non-resectable Brain Metastases Treated With Radiation Therapy With Palliative Intent[NCT02844387] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Phase I/II Trial Of Weekly Irinotecan And Docetaxel With The Addition Of Celecoxib In Advanced Non-Small Cell Lung Cancer[NCT00073866] | Phase 1/Phase 2 | 0 participants | Interventional | 2003-06-30 | Completed | ||
| A Phase I Trial Of A COX-2 Inhibitor (Celecoxib) In Combination With An EGFR Inhibitor (OSI-774) In Metastatic Non-Small Cell Lung Cancer[NCT00072072] | Phase 1 | 0 participants | Interventional | 2003-08-31 | Completed | ||
| A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553] | Phase 2 | 0 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2018-01-29 | Terminated (stopped due to Difficult to enrollment patient) | ||
| Randomized Phase II Study of Eicosanoid Pathway Modulators and Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer[NCT00070486] | Phase 2 | 140 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 61.04 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 55.06 |
Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 11.4 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 12.5 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the first quartile (Q1, 10.09). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q1 | 7.7 |
| PGE-M >= Q1 | 4.9 |
prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q2, 15.38). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q2 | 6.2 |
| PGE-M >= Q2 | 4.2 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q3, 27.86). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q3 | 6.0 |
| PGE-M >= Q3 | 3.0 |
Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and disease relapse or death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 5.16 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 5.26 |
The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients. Response rates (including complete and partial response) will be tested using Fisher's exact test (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 40 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 35 |
"Patients were followed for at least 90 days from start of RT and carefully evaluated with respect to treatment morbidity. A dose limiting toxicity (DLT) was defined as grade 3 or 4 nonhematologic (excluding nausea, vomiting, and alopecia) and grade 4 hematologic toxicities. Six patients were to be accrued at each dose level. If no more than three of the six patients experienced a DLT then that dose level was considered acceptable and dose escalation occurred by accruing six more patients at the next dose level. Otherwise, the preceding dose level, if any, would be declared the MTD. The MTD would be used for the Phase II arm. At a given dose, the probability of halting dose escalation when the true toxicity is 50% or higher is at least 66% (power). In addition, if the true DLT rate is instead 20%, there will still be a 10% probability of halting dose escalation at a given dose level (type I error).~Rating scale: 0 = not the MTD, 1 = MTD" (NCT00046839)
Timeframe: Start of treatment to 90 days
| Intervention | units on a scale (Number) |
|---|---|
| Phase I: Celecoxib 200mg BID + RT | 0 |
| Phase I: Celecoxib 400mg BID + RT | 1 |
Because only 21 patients (18 analyzable) out of 128 planned were accrued on this study, all analyzable patients were combined to report overall survival. The original study design planned for a comparison to a historical control, but due to the small number of patients, survival time is only reported, not tested. (NCT00046839)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 12 months.
| Intervention | years (Median) |
|---|---|
| Experimental: Phase I/II: Celecoxib 200 or 400mg BID + RT | 10.0 |
For determining progression-free survival, progression was determined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progression was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00771953)
Timeframe: From the date of randomization until the first date that recurrent or progressive disease is objectively documented.
| Intervention | days (Median) |
|---|---|
| Apricoxib Plus Docetaxel | 75 |
| Placebo Plus Docetaxel | 97 |
| Apricoxib Plus Pemetrexed | 103 |
| Placebo Plus Pemetrexed | 98 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
15 reviews available for celecoxib and Lung Neoplasms
| Article | Year |
|---|---|
The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; ErbB Receptors; Humans; Lung Neoplasms; | 2022 |
Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Lung Neoplasms; Publ | 2018 |
Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cardiovascul | 2014 |
Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Lung Ne | 2016 |
Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Disco | 2015 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Ch | 2009 |
Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Celecoxib; Clinical Trials as Topic; Humans; Ki-67 Antigen | 2010 |
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Ce | 2003 |
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Celecoxib; Cisp | 2003 |
Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cele | 2003 |
Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Humans | 2004 |
COX-2 inhibition and lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung | 2004 |
Celecoxib and radiation therapy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topi | 2004 |
[Cyclooxygenase 2 inhibitors and lung carcinoma].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cele | 2004 |
Perspectives on novel therapies for bronchial carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2005 |
41 trials available for celecoxib and Lung Neoplasms
| Article | Year |
|---|---|
Intercostal block vs. epidural analgesia in thoracoscopic lung cancer surgery: a randomized trial.
Topics: Adult; Aged; Analgesia, Epidural; Analgesics; Celecoxib; Female; Humans; Japan; Lung Neoplasms; Male | 2020 |
Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemoradi | 2019 |
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Celecoxib; Cyclo | 2017 |
A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.
Topics: Aged; Cachexia; Celecoxib; Combined Modality Therapy; Dietary Supplements; Disease Management; Exerc | 2017 |
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemoradioth | 2014 |
Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Celecoxib; Humans; Lung Neoplasms; Pyrazoles; Random All | 2014 |
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2015 |
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2008 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase I | 2009 |
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecox | 2008 |
Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Cyclooxygenase 2 | 2009 |
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2009 |
Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers.
Topics: Adult; Advertising; Aged; Aged, 80 and over; California; Celecoxib; Chemoprevention; Clinical Trials | 2009 |
Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Proliferation; D | 2010 |
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclo | 2011 |
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cycloox | 2011 |
Lung cancer chemoprevention with celecoxib in former smokers.
Topics: Biomarkers, Tumor; Bronchi; Bronchoalveolar Lavage; C-Reactive Protein; Celecoxib; Cross-Over Studie | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arac | 2011 |
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.
Topics: Adult; Amino Acids, Essential; Cachexia; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modalit | 2011 |
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell | 2013 |
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cachexi | 2004 |
Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Celecoxib; Combined Modality Therapy; Cyclooxygenase | 2005 |
Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 2005 |
A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Combined | 2005 |
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Ant | 2005 |
Celecoxib decreases Ki-67 proliferative index in active smokers.
Topics: Aged; Bronchi; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Immunohisto | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2006 |
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 2007 |
Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; C | 2007 |
Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Appetite; C-Reactive Protein; Cachexia; Celecoxib; Cohort Studies; C | 2007 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-C | 2008 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell L | 2008 |
115 other studies available for celecoxib and Lung Neoplasms
| Article | Year |
|---|---|
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carcinoma, Non-Small-C | 2016 |
PACER lncRNA regulates COX-2 expression in lung cancer cells.
Topics: Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cytokines; Dinoprostone; Humans; Inflammation; Lung; | 2022 |
Implications and Efficacy of Aromatase Inhibitors in Combination and Monotherapy for the Treatment of Lung Cancer.
Topics: Agar; Annexins; Apoptosis; Aromatase; Aromatase Inhibitors; Celecoxib; Cell Line, Tumor; Cell Prolif | 2022 |
Simultaneous pulmonary administration of celecoxib and naringin using a nebulization-friendly nanoemulsion: A device-targeted delivery for treatment of lung cancer.
Topics: Celecoxib; Emulsions; Flavanones; Humans; Lung Neoplasms; Nanoparticles; Particle Size | 2022 |
Triple targeting of mutant EGFR
Topics: Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2; Diclofenac; ErbB Receptors; Humans; Lung Neop | 2023 |
Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression.
Topics: Apoptosis; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferat | 2023 |
Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation | 2019 |
Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer.
Topics: A549 Cells; Animals; Biological Transport; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chitosan; Dela | 2020 |
Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer.
Topics: Antineoplastic Agents, Immunological; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2 Inhibitors; Dru | 2020 |
Celecoxib and Afatinib synergistic enhance radiotherapy sensitivity on human non-small cell lung cancer A549 cells.
Topics: A549 Cells; Afatinib; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Survival; Cyclooxyg | 2021 |
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung | 2022 |
Pulmonary Delivery of Docetaxel and Celecoxib by PLGA Porous Microparticles for Their Synergistic Effects Against Lung Cancer.
Topics: Celecoxib; Docetaxel; Drug Carriers; Humans; Lactic Acid; Lung Neoplasms; Particle Size; Porosity | 2022 |
Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.
Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Celecox | 2017 |
Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes.
Topics: Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytoplasm; Dinoprostone; | 2018 |
Identification of key genes and long non‑coding RNAs in celecoxib‑treated lung squamous cell carcinoma cell line by RNA‑sequencing.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; High- | 2018 |
IL-1β-Mediated Up-Regulation of WT1D via miR-144-3p and Their Synergistic Effect with NF-κB/COX-2/HIF-1α Pathway on Cell Proliferation in LUAD.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Animals; Antagomirs; Celecoxib; Cel | 2018 |
Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Ce | 2018 |
Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2019 |
Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzo(a)pyrene; Bron | 2013 |
Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Humans; Ifosfamide; Lung Neoplasms | 2013 |
Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tu | 2013 |
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Down-Regulation; Gene Expression | 2014 |
Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase | 2013 |
[Effects of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway.
Topics: Animals; Antigens, CD; beta Catenin; Cadherins; Celecoxib; Cell Line, Tumor; Cell Proliferation; Din | 2014 |
PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclo | 2014 |
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lun | 2014 |
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, No | 2014 |
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Celecoxib; Cell Line, Tumor; | 2014 |
A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.
Topics: Animals; Celecoxib; Diet Therapy; Diet, Carbohydrate-Restricted; Dietary Proteins; Disease Models, A | 2014 |
Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Breast Neoplas | 2014 |
Prostanoid induces premetastatic niche in regional lymph nodes.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Celecoxib; Cell Line, Tumor; Chemokine CXCL12 | 2014 |
Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relat | 2014 |
Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Fema | 2014 |
Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell L | 2015 |
Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway.
Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxyge | 2015 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; C | 2015 |
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell | 2015 |
Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.
Topics: Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Humans; Intercellular Adhesion Molecule-1; | 2015 |
Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1.
Topics: A549 Cells; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials, Ph | 2017 |
Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle Checkpo | 2017 |
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.
Topics: Animals; Celecoxib; Cell Polarity; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Model | 2017 |
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Ce | 2008 |
Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 | 2008 |
Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Chromones; Cisplatin; Cyclooxygenase In | 2009 |
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small | 2009 |
The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dendritic Cells; Dinoprostone; Fo | 2009 |
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Autoimmune Dise | 2009 |
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2009 |
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; | 2009 |
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2010 |
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Di | 2011 |
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 In | 2011 |
The dawn of a revolution in personalized lung cancer prevention.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Lung Neoplasms; Male; Pyrazoles; Smoking; Su | 2011 |
Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Ben | 2012 |
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone Neoplasms; Celecoxib; Collagen Type | 2011 |
COX-2 inhibitor, celecoxib, may prevent lung cancer.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Ki-67 Antigen; Lung Neoplasms; Pyrazoles; Sulfonamid | 2011 |
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Topics: Angiogenesis Inhibitors; Celecoxib; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2013 |
Celecoxib may prevent lung cancer.
Topics: Celecoxib; Humans; Lung Neoplasms; Pyrazoles; Smoking Cessation; Sulfonamides | 2012 |
ROC curve estimation under test-result-dependent sampling.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials, Phase III as Topic; Computer | 2013 |
Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cisplatin; Cyclooxygenase 2 Inhibitors; Female; Lung Neop | 2012 |
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cycloo | 2012 |
Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis.
Topics: Animals; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytokines; Female; Inflammation; | 2013 |
Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts.
Topics: Abdominal Neoplasms; Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line | 2013 |
Different cell cycle modulation by celecoxib at different concentrations.
Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Cyclooxygen | 2013 |
Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2013 |
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Topics: Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cycloo | 2013 |
Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Bu | 2002 |
Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Celecoxib; Cell Division; Cell Line, Tu | 2003 |
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.
Topics: Aged; Bronchoalveolar Lavage; Bronchoscopy; Calcimycin; Carcinoma, Non-Small-Cell Lung; Case-Control | 2003 |
Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells.
Topics: Alprostadil; Celecoxib; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; DNA; Eic | 2004 |
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; | 2004 |
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2004 |
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Topics: Carcinogens; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclin D1; Cyclooxygenase | 2004 |
Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Line, Tumor; Cell Survival | 2004 |
Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Drug Interactions; Drug Therapy, Combin | 2004 |
Celecoxib: a novel treatment for lung cancer.
Topics: Administration, Oral; Celecoxib; Clinical Trials as Topic; Combined Modality Therapy; Cyclooxygenase | 2004 |
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.
Topics: Amiloride; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibit | 2004 |
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Northern; Blotting, Weste | 2004 |
Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.
Topics: Aerosols; Celecoxib; Cell Line, Tumor; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; | 2005 |
Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Celecoxib; Ce | 2005 |
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; B | 2005 |
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Topics: Adenocarcinoma; Animals; Celecoxib; Cells, Cultured; Cyclooxygenase Inhibitors; Disease Models, Anim | 2005 |
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibi | 2006 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2005 |
Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells.
Topics: Bronchi; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Re | 2005 |
Could the combination of celecoxib and 4HPR be an effective lung cancer treatment?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2 I | 2005 |
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu | 2005 |
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lung N | 2005 |
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.
Topics: Animals; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibitors; Lung Neoplasms; Mal | 2006 |
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
Topics: Alitretinoin; Animals; Antineoplastic Agents; Carcinogens; Celecoxib; Cell Transformation, Neoplasti | 2006 |
Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene.
Topics: Anticarcinogenic Agents; Blotting, Western; Catechin; Celecoxib; Cell Line, Tumor; Cyclooxygenase In | 2006 |
Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Celecoxib; Cyclooxygenase 2; Cycloox | 2006 |
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Topics: Aerosols; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; C | 2006 |
PGE2 produced by lung cancer suppresses immune function through T-regulatory cells and can be blocked by the COX2 inhibitor Celebrex.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Immune Tolerance; Lung Neoplasms; Pyra | 2005 |
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Topics: Adenocarcinoma; Animals; Blotting, Western; Celecoxib; Cell Adhesion; Cyclooxygenase 2 Inhibitors; D | 2006 |
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytoge | 2006 |
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Combined | 2006 |
Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.
Topics: Anticarcinogenic Agents; Apoptosis; Bronchi; Bronchial Diseases; Celecoxib; Cell Line, Tumor; Cells, | 2006 |
Did targeted therapy fail cyclooxygenase too?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxyg | 2006 |
Paired drugs give advanced lung cancer a double punch.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Drug Therapy, Combination | 2006 |
Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regulati | 2006 |
Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; bcl-X Protein; Celecoxib; Cell Line, Tu | 2007 |
Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.
Topics: 5-Lipoxygenase-Activating Proteins; Apoptosis; Blotting, Western; Carrier Proteins; Celecoxib; Cell | 2007 |
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Chem | 2007 |
CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD | 2007 |
Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibito | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2 | 2007 |
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.
Topics: Adenocarcinoma; Animals; Carcinogens; Celecoxib; Cricetinae; Cyclooxygenase 2; Cyclooxygenase Inhibi | 2007 |
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non- | 2008 |
Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; C | 2008 |
Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Animals; Arachidonic Acid; Celecoxib; Chromatography, Hi | 2001 |